Table 4.

Prognostic factors associated with overall survival (OS) and disease-free survival (DFS) in multivariate analysis

Risk factors	P-value	HR	95% CI
Overall survival
Recurrence after completing post-operative chemotherapy	0.052	1.77	[0.97–3.23]
Size of metastases	0.300	1.07	[0.50–2.28]
Local treatment	0.075	2.41	[0.91–6.35]
Major hepatectomy	0.750	1.12	[0.53–2.28]
Bevacizumab use	0.475	1.45	[0.24–1.92]
Disease-free survival
Lymph node-positive primary tumour	0.011	1.68	[1.12–2.50]
Synchronous disease	0.041	1.65	[1.02–2.67]
Age	0.113	1.30	[0.93–1.82]
Number of pre-operative cycles	0.798	1.04	[0.72–1.50]
Bevacizumab use	0.408	1.19	[0.78–1.81]

HR, hazard ratio; CI, confidence interval.